Option chain shows key data for Barinthus Biotherapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Barinthus Biotherapeutics.

Barinthus Biotherapeutics (NASDAQ:BRNS) Stock, Option Chain

Barinthus Biotherapeutics

Vaccitech

Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer.

Movers

News

Pre-Market Outlook

Markets

Trading Ideas

BRNS

CLOV

DMTK

ENSC

IPDN

LGHL

MGOL

MOLN

ONDS

RELI

SLDB

SPEC

SRPT

TPHS

TRVN

ZCAR

Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket

laboratory-217041_1280

Analyst Color

Biotech

Health Care

Analyst Ratings

General

Explore the latest findings from Barinthus Biotherapeutics on VTP-200&#39;s performance in the APOLLO trial for low-grade cervical lesions linked to persistent hrHPV infection. Positive trends were noted, though not statistically significant. No major safety concerns were observed.

Infection-Focused Barinthus Bio&#39;s VTP-200 Data Underwhelming: Analyst Weighs On Mixed Perspectives

Penny Stocks

SYBX

Synlogic, Inc. (NASDAQ: SYBX) came out with a quarterly loss of $1.71 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to loss of $3.60 per share a year ago. These figures are adjusted for non-recurring items.

Synlogic, Inc. (SYBX) Reports Q4 Loss, Tops Revenue Estimates

Barinthus Biotherapeutics plc - American Depositary Shares

Barinthus Biotherapeutics PLC

Earnings

Press Releases

Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results

Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease

Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer

Barinthus Bio Announces Late Breaking Presentation at AASLD 2024 – The Liver Meeting® and Attendance at November Conferences

Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B

Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion

Management

Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer

Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update

Events

Barinthus Biotherapeutics plc to Present at the Investor Summit Virtual on March 11

ABUS

Agenus

AlloVir

ALX Oncology Holdings Inc. - Common Stock

ALX Oncology Holdings

Alterity Therapeutics Limited - American Depositary Shares

Alterity Therapeutics

Atara Biotherapeutics, Inc. - Common Stock

Atara Biotherapeutics

Connect Biopharma Holdings Limited - American Depositary Shares

Connect Biopharma Hldgs

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

Dyadic International, Inc. - Common Stock

Dyadic International

Fortress Biotech

Forte Biosciences

FibroGen

ImmuCell

Immix Biopharma

Kala Bio

Kezar Life Sciences

Lantern Pharma

MAIA Biotechnology

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

Radiopharm Theranostics Limited - American Depositary Shares

Radiopharm Theranostics

Rein Therapeutics

Serina Therapeutics

Spero Therapeutics

Surrozen

Exicure

Xilio Therapeutics

HC Wainwright & Co.

Alliance Global Partners

Barclays

Comments

Barinthus Biotherapeutics

Barinthus Biotherapeutics (BRNS) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga